ROIVW

Roivant Sciences (ROIVW)

Roivant Sciences Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ROIVW

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/30	20 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2024/05/17	05 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	NASDAQ:ROIVW	Roivant Sciences Ltd
2024/04/02	20 : 00	GlobeNewswire Inc.	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	NASDAQ:ROIVW	Roivant Sciences Ltd
2024/02/13	21 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2024/01/31	06 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/12/21	06 : 30	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/12/14	23 : 00	GlobeNewswire Inc.	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/11/28	21 : 00	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/11/27	22 : 00	GlobeNewswire Inc.	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/11/13	21 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/11/10	22 : 00	GlobeNewswire Inc.	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/10/31	06 : 30	GlobeNewswire Inc.	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/10/23	14 : 00	GlobeNewswire Inc.	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/09/26	19 : 00	GlobeNewswire Inc.	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/09/11	21 : 00	GlobeNewswire Inc.	Roivant Announces Completion of Redemption of its Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/08/18	05 : 05	GlobeNewswire Inc.	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/08/14	20 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/08/04	05 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/08/03	05 : 05	GlobeNewswire Inc.	Roivant Announces Redemption of Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/07/27	21 : 00	GlobeNewswire Inc.	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/07/14	12 : 06	KR Market News	로이반트, 로슈에 $70억 가치의 장 치료제 판매 협상 중	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/07/11	21 : 00	GlobeNewswire Inc.	Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/06/28	21 : 57	GlobeNewswire Inc.	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/06/28	20 : 00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/06/27	05 : 05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/06/22	20 : 30	GlobeNewswire Inc.	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/06/22	06 : 00	GlobeNewswire Inc.	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/05/16	20 : 00	GlobeNewswire Inc.	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/03/28	21 : 00	GlobeNewswire Inc.	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients	NASDAQ:ROIVW	Roivant Sciences Ltd
2023/03/15	20 : 45	GlobeNewswire Inc.	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old	NASDAQ:ROIVW	Roivant Sciences Ltd